We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Dana-Farber's personalized vaccine NeoVax showed median survival of 36.9 months in glioblastoma at ASCO 2026. Learn how immunotherapy works and who it suits.
